thin endometrium
Conditions
Interventions
Experimental group:umbilical cord blood mononuclear cells
Control group:None
Sponsors
Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University
Eligibility
Sex/Gender
Female
Age
20 Years to 39 Years
Inclusion criteria
Inclusion criteria: 1. Sign the informed consent form voluntarily; 2. Married women aged 20 to 39 years; 3. Body mass index (BMI) 18-30kg/m^2; 4. In vitro fertilization-embryo transfer (IVF-ET) or intracytoplasmic sperm injection technology (ICSI) indications; 5. At least 3 months using artificial cycles, endometrial stimulation, sildenafil, aspirin, ovulation induction programs, etc. Make the endometrial thickness on the day of ovulation or progesterone>7mm; 6. No obvious abnormality was found in hysteroscopy.
Exclusion criteria
Exclusion criteria: 1. Patients with recurrent miscarriage who have had spontaneous abortions >= 3 times; 2. Those who have participated in other clinical trials within 3 months before screening and have used study drugs; 3. Those who have undergone other intrauterine injections within 3 months before screening, such as granulocyte colony stimulating factor, bone marrow mesenchymal stem cells, platelet-enriched plasma, etc.; 4. Those who have clinically significant abnormal cervical examination results within 3 months before screening; 5. Currently patients with acute infections of the urinary and reproductive systems; 6. According to the judgment of the researcher, those who have major systemic diseases, major endocrine or major metabolic abnormalities that are not suitable for participating in this research; 7. According to the investigators judgment, those who have uterine (such as submucosal uterine fibroids, intramuscular uterine fibroids larger than 3cm or smaller than 3cm but affecting the shape of the uterine cavity, untreated endometrial polyps, intrauterine adhesions, patients with uterine effusion, uterine malformations, ASRM III~IV endometriosis, adenomyosis), ovaries (ovarian cysts> 4cm) or appendages (such as hydrosalpinx) abnormalities with clinical significance; 8. Patients with abnormal uterine bleeding of unknown cause; 9. Those with a history of malignant tumors such as ovaries, breasts, uterus, hypothalamus, and pituitary gland; 10. Known past or current thromboembolic diseases; 11. Those who have a known serious mental illness or cannot understand the purpose and methods of the clinical trial, and who do not follow the research procedures; 12. Those who have contraindications to the use of GnRH-a, r-hFSH, hCG, and progesterone drugs or have a history of allergies; 13. Those who have bad habits of alcoholism, smoking, drug abuse, or drug abuse; 14. Exposure to teratogenic radiation, poisons, and drugs and in the active period; 15. Those who are HIV or syphilis positive; 16. Those who have fever on the day of infusion; 17. Other reasons why the researcher thinks it is not suitable to participate in this research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| embryo implanta-tion rate;clinical pregnant rate;ongoing pregnant rate;delivery rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Subendometrial blood flow;endometrial thickness; | — |
Countries
China
Contacts
Public ContactDeng Xiaohui
Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University
Outcome results
None listed